Daratumumab proves safe and highly effective in AL amyloidosis

Br J Haematol. 2019 Apr;185(2):342-344. doi: 10.1111/bjh.15455. Epub 2018 Jun 25.

Authors

Affiliations

¹ Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
² Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
³ Department of Internal Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH, USA.

PMID: 29938774
DOI: 10.1111/bjh.15455

No abstract available

Keywords: AL amyloidosis; daratumumab; monoclonal antibodies; multiple myeloma.

Publication types

Multicenter Study

MeSH terms

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Drug Administration Schedule
Female
Humans
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Male
Middle Aged
Multiple Myeloma / drug therapy
Recurrence
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents
daratumumab